NCT00514085 2023-08-04
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
11 trialsNCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT00568763 2018-10-31
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02236546 2017-04-13
FDG-PET in Advanced Melanoma
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT00049010 2016-07-01
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Alliance for Clinical Trials in Oncology
Phase NA Completed
NCT01316692 2016-05-30
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01339663 2014-04-21
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00438984 2012-03-16
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00602199 2011-05-16
ABT-510 in Treating Patients With Metastatic Melanoma
Mayo Clinic
Phase 2 Completed
NCT00667901 2009-12-11
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
Phase 1 Terminated